AltraVue Capital’s Lifecore Biomedical LFCR Stock Holding History

AltraVue Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-383,592	Closed	-$4.07M	–	34
2021 Q1	$4.07M	Sell	383,592 -258,701	-40%	-$2.91M	0.9%	29
2020 Q4	$6.97M	Buy	642,293 +211,540	+49%	+$2.19M	2.08%	26
2020 Q3	$4.19M	Buy	430,753 +89,463	+26%	+$852K	1.96%	23
2020 Q2	$2.72M	Sell	341,290 -9,150	-3%	-$94.4K	2.04%	17
2020 Q1	$3.04M	Sell	350,440 -199,585	-36%	-$2.08M	2.52%	13
2019 Q4	$6.22M	Sell	550,025 -12,200	-2%	-$130K	3.09%	17
2019 Q3	$6.11M	Sell	562,225 -4,820	-0.9%	-$52.5K	3.36%	12
2019 Q2	$5.31M	Buy	567,045 +77,470	+16%	+$782K	2.94%	19
2019 Q1	$6.01M	Buy	489,575 +136,820	+39%	+$1.67M	3.4%	12
2018 Q4	$4.18M	Buy	+352,755	New	+$4.84M	2.63%	18

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AltraVue Capital's LFCR Position: Q2 2021 in Review

AltraVue Capital sold out of Lifecore Biomedical (LFCR) in Q2 2021, closing a stake of 383,592 shares — an estimated $4.07M sold.

AltraVue Capital first reported a position in LFCR in Q4 2018 and held it in 10 quarters. The position peaked at $6.97M in Q4 2020. 95 funds tracked by Wall St. Rank hold LFCR as of Q2 2021.

AltraVue Capital reported no remaining Lifecore Biomedical position as of Q2 2021 after selling out during the quarter.
AltraVue Capital sold 383,592 Lifecore Biomedical shares in Q2 2021, an estimated $4.07M.
AltraVue Capital first reported a position in Lifecore Biomedical in Q4 2018 and held it in 10 quarters.
AltraVue Capital's Lifecore Biomedical position peaked at $6.97M in Q4 2020.
95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2021.

Based on AltraVue Capital's 13F filing for Q2 2021, filed 30 Jul 2021.